Showing recent highlights
What's New
PubMed (Open Access Guidelines) · December 1, 2026
A study looked at data from over 17,000 people with early-stage breast cancer to compare different chemotherapy combinations and schedules. Researchers found that certain combinations and timing of chemotherapy drugs — specifically giving some drugs together versus one after another — appeared to work better at helping people stay cancer-free and live longer. People with early-stage breast cancer may want to ask their doctor how the timing and combination of their chemotherapy plan compares to the latest research findings.
What's New
PubMed · September 2, 2026
A study found that using a glowing dye called indocyanine green (ICG) — which lights up under a special camera — to locate sentinel lymph nodes (the first lymph nodes that cancer might spread to) in early breast cancer worked better than the traditional blue dye currently used. ICG found the right nodes every single time and took less time to work, while the blue dye missed the target nodes in 1 out of 4 patients in this small study. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that taking 6 mg of melatonin daily helped breast cancer patients sleep better while going through chemotherapy — specifically, they fell asleep more easily and slept more efficiently compared to patients who took a placebo (a sugar pill with no active ingredient). The study also found some improvement in anxiety levels during one phase of chemotherapy. This is early research and hasn't yet changed treatment guidelines.
Ask your doctor: Ask the doctor whether taking 6 mg of melatonin daily might help the patient sleep better and feel less anxious or depressed during chemotherapy treatment.
What's New
PubMed · September 1, 2026
Researchers found that immune cells called tumor-infiltrating lymphocytes (TILs) — which are infection-fighting cells that move into a tumor — can be measured using traditional methods, computer software, or artificial intelligence, and that higher levels of these cells were linked to better outcomes in people with an aggressive form of breast cancer called HER2-positive breast cancer. The AI-based measurement tools performed about as well as trained specialists at identifying these immune cells, which could eventually make this type of testing faster and more widely available. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
A study found that a hormone called AMH — which reflects how active a woman's ovaries are — may help predict whether adding chemotherapy to hormone-blocking treatment is actually helpful for certain women with breast cancer. Specifically, researchers found that premenopausal women with normal ovarian activity (AMH at or above a certain level) had significantly better outcomes when they received chemotherapy alongside hormone-blocking treatment, while women with lower ovarian activity did not seem to benefit from adding chemotherapy. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that the physical and emotional changes that come with breast cancer treatment — such as shifts in how women feel about their bodies — can create real challenges for sexual intimacy and romantic relationships, and these struggles are often not brought up by healthcare providers. The review also found that for women starting new relationships after a diagnosis, deciding when and how to share their health history with a partner played a big role in how close those relationships became. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that doing structured exercise before breast cancer surgery — sometimes called 'prehabilitation' — did not significantly reduce pain in the month after surgery, based on a review of several studies involving over 500 women. The exercise programs varied a lot in length and type, which made it harder to draw firm conclusions. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that while many young women (ages 15–30) have heard of breast cancer, most don't know much about its warning signs or how to check their own breasts for changes — and very few actually do those self-checks regularly. The gap seems to come down to a mix of reasons: not having enough solid information, feeling like breast cancer 'won't happen to me,' and cultural or emotional barriers that get in the way. This matters because catching breast cancer early can make a real difference in outcomes, so understanding what's stopping young women from checking themselves is an important step toward better support. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that in people who had breast reconstruction using an implant after mastectomy, the type of internal support material used — either one made from natural tissue (called biologic mesh) or a man-made material (synthetic mesh) — didn't make a significant difference in how often complications occurred. However, where the implant was placed mattered quite a bit: placing it under the chest muscle was linked to much higher rates of implant loss and a complication called capsular contracture, where scar tissue tightens painfully around the implant, compared to placing it on top of the muscle. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that a breast cancer diagnosis can deeply affect the relationship between a mother and her children — not just emotionally, but in everyday family life. Across 68 studies, the vast majority found that mothers worried about their children, that both mothers and kids experienced significant emotional strain, and that children often took on extra responsibilities at home after the diagnosis. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
A study found that for people who had a mastectomy (surgery to remove the breast) and chose to have breast reconstruction done later, the type of reconstruction technique used may affect both quality of life and how many follow-up surgeries are needed. Specifically, researchers found that a method using a temporary tissue expander — a device placed under the skin to gradually stretch it before a final implant — was linked to a meaningful improvement in quality of life and fewer additional surgeries over roughly 13 years compared to another technique, in people who had not previously received radiation therapy. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
A study found that women with a type of advanced breast cancer (called hormone receptor-positive, HER2-negative) who took palbociclib combined with tamoxifen reported a similar overall quality of life compared to those who took tamoxifen alone — meaning the added medication didn't make them feel noticeably worse day-to-day. The study also found that patients taking the combination went longer before experiencing a meaningful increase in pain — about 32 months compared to about 21 months for those on tamoxifen alone. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
A study involving nearly 5 million breast cancer patients found that waiting longer for surgery after a diagnosis was linked to worse survival — and the risk grew the longer the wait. Compared to having surgery within 30 days, waiting 30–59 days was associated with an 8% higher risk of death, waiting 60–89 days with a 12% higher risk, and waiting 90–120 days with a 37% higher risk. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that for postmenopausal women with a specific type of early breast cancer (one that is fueled by estrogen but not by a protein called HER2), a tumor gene test called Oncotype DX may help predict who actually needs chemotherapy on top of hormone-blocking treatment. Patients whose test showed a high risk score seemed to do better when chemotherapy was added — but those who also responded well to hormone treatment before surgery didn't show the same clear benefit from chemotherapy, suggesting that combining the gene test results with how a tumor responds to early treatment could help doctors make more personalized decisions. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that among bone-strengthening drugs called bisphosphonates — used to protect the bones of people with breast cancer that has spread there — different medications may have different strengths: one called clodronate appeared best at reducing fractures caused by weakened bones, while zoledronate seemed most effective at managing high calcium levels in the blood (a dangerous complication of bone spread), and ibandronate caused the fewest side effects. This matters because doctors treating bone metastases (cancer that has traveled to the bones) may be able to match the best medication to each patient's specific needs. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
A study found that trolamine — a cream sometimes used to soothe skin during radiation therapy — may help protect breast cancer patients from serious skin reactions caused by radiation treatment. Researchers looked at 10 studies involving 980 patients and found that those who used trolamine were less likely to develop moderate to severe skin irritation, like painful redness, blistering, or open sores. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
A study found that among people with an advanced form of HER2-positive breast cancer (a type where a specific protein fuels cancer growth), those who took a chemotherapy drug called eribulin held onto a better quality of life for longer — about 7 months — compared to about 4.5 months for those who took a common group of chemotherapy drugs called taxanes. Researchers found that people in the taxane group experienced a noticeable dip in how they felt during treatment, while those on eribulin had more stable day-to-day wellbeing over the course of the study. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that a special full-body scan called HER2-targeted PET/CT — which looks for a specific protein called HER2 that can fuel some breast cancers — was fairly good at spotting tumors where that protein is present, even in different parts of the body at the same time. This matters because HER2 levels can vary between tumors in the same person, and knowing where HER2 is active helps doctors choose the right treatment. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that in people with a hard-to-treat form of breast cancer called triple-negative breast cancer, certain patterns of gene activity in tumor tissue — measured early during treatment — could help predict who was most likely to respond well to a combination of chemotherapy and immunotherapy (a treatment that helps the immune system fight cancer). Specifically, tumors that showed early signs of fewer actively dividing cancer cells and a stronger immune response after just one round of treatment were much more likely to be completely gone by the time of surgery. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that using special tools called 'decision aids' — things like videos, booklets, or websites that help patients understand their options — made a real difference for people facing breast reconstruction surgery after a mastectomy (surgery to remove the breast). Patients who used these tools felt more informed and less torn about their choices, with knowledge improving by 15–30% and feelings of uncertainty dropping significantly. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
A study found that breast cancer survivors who did more moderate to vigorous physical activity — like brisk walking or cycling — tended to report a better quality of life, including better physical health and overall well-being. Interestingly, survivors who were more than two years past their diagnosis seemed to benefit even more from that activity when it came to quality of life scores. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that for people with a hard-to-treat form of breast cancer called triple-negative breast cancer, using ultrasound to help deliver chemotherapy drugs directly into tumors may improve how well the treatment works and help patients feel better during treatment compared to a standard chemotherapy combination. The ultrasound approach also appeared to help protect the immune system — the body's natural defense network — from being weakened by treatment, which could matter for how patients recover. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
A study found that a specific tumor test called the SETER/PR index — which measures how responsive a breast cancer tumor is to hormone-blocking treatments — may help predict which patients with hormone-sensitive breast cancer are most likely to benefit from adding a chemotherapy drug called paclitaxel to their treatment plan. Patients whose tumors scored low on this index appeared to do significantly better when paclitaxel was added, while those with higher scores saw no added benefit from the extra chemotherapy. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
A study found that for people with a type of breast cancer called triple-negative breast cancer — which is harder to treat because it lacks certain proteins that other therapies can target — adding newer drugs to standard chemotherapy may help more patients reach what doctors call a 'complete response,' meaning no cancer cells are detectable in the body after treatment. Specifically, researchers found that combining standard chemo with platinum-based drugs, immune-boosting drugs (called checkpoint inhibitors), or a newer class called PARP inhibitors was linked to significantly better results than standard chemotherapy alone. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that a group of breast cancer drugs called CDK4/6 inhibitors — which includes medications like palbociclib, ribociclib, and abemaciclib — were linked to a higher risk of liver problems compared to not taking them, based on data from over 24,000 patients. Specifically, three of the four drugs studied showed signs of liver stress, most often seen as elevated liver enzymes (proteins in the blood that signal the liver may be under strain), while a fourth drug called dalpiciclib did not show the same pattern. People with breast cancer taking these medications may want to be aware of this finding and speak with their doctor about monitoring their liver health. This is early research and hasn't yet changed treatment guidelines.
Ask your doctor: Ask the doctor whether the patient should have liver function tests done regularly while taking CDK4/6 inhibitors like palbociclib, ribociclib, or abemaciclib, since research shows these drugs can sometimes cause liver problems.
What's New
PubMed · September 1, 2026
Researchers found that breast cancer patients going through chemotherapy tend to fall into two distinct groups when it comes to side effects like nausea, anxiety, low mood, and sleep problems — those with milder symptoms and those with more severe ones. The study looked at two hands-on techniques: transcutaneous electrical acupoint stimulation (TEAS), which uses a small device to send gentle electrical pulses to specific points on the skin, and self-acupressure (SA), where patients apply firm finger pressure to those same points themselves. Researchers found that these approaches may help ease that cluster of side effects differently depending on which group a patient fell into, suggesting that matching the right technique to the right person could matter. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that a special type of ultrasound imaging called shear wave elastography — which measures how stiff a tumor is — may help doctors tell whether breast cancer is responding to chemotherapy given before surgery. Looking at 15 studies involving over 1,400 patients, researchers found the technique showed a moderate ability to predict whether the cancer had responded well to treatment, meaning it correctly identified responders and non-responders a reasonable but not perfect amount of the time. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that new types of imaging agents — including tiny particles called nanoparticles and ultrasound-based bubbles — may be able to identify specific types of breast cancer tumors more precisely than traditional scans like MRI or CT, which sometimes struggle to tell different tumor types apart. This matters because more precise imaging could potentially help doctors choose the right treatment for each person's specific cancer. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that a blood test capable of detecting tiny fragments of cancer DNA — called circulating tumor DNA — was able to spot signs of breast cancer returning in most patients about 8 months before they had any symptoms, even when taken two years after finishing chemotherapy. Among patients whose blood test came back positive, the vast majority went on to develop cancer that had spread to other parts of the body, suggesting this type of test could give doctors an earlier window to act. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that women with breast cancer who took part in a professionally led support group called the Mind Support Group reported feeling very positive about the experience — saying it helped them cope better emotionally, feel less alone, and open up about their experiences in ways that felt healing. The 22 women in the study said the group helped them shift toward healthier ways of handling the stress of their diagnosis and treatment, and their main suggestions were simply to start the groups earlier and offer in-person options. This is early research and hasn't yet changed treatment guidelines.
For informational purposes only. Not medical advice. Always consult a physician before making any health decisions.